Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02949362 · ClinicalTrials.gov registry record · Phase 3

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

A Phase 3 study, sponsored by Shire.

Completed
Registry status
Phase 3
Development phase
29
Enrollment target

NCT02949362 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 29 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02949362, a Phase 3 study, has completed, sponsored by Shire.

COMPLETED
Registry status
Phase 3
Development phase
29 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period. It will evaluate how these children fared after the TED-C13-003 study ended. This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C13-003.

Interventions

  • OTHER SOC
  • DRUG Teduglutide

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2016-12-09
Est. Completion 2020-07-14
Phase Phase 3

Sponsor

Shire

245 total trials

What the Registry Record Tells You About NCT02949362

The ClinicalTrials.gov registry entry for NCT02949362 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which SOC is the first listed.

NCT02949362 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02949362 about?

NCT02949362 is a clinical study titled "Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study". The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period. It will evaluate how these children fared after the TED-C13-003 study ended. This study will also offer t...

What is the current status of trial NCT02949362?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2016-12-09. Estimated completion is 2020-07-14.

What interventions are being tested in trial NCT02949362?

The interventions under investigation include: SOC (OTHER), Teduglutide (DRUG).

Who is sponsoring clinical trial NCT02949362?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.